Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia

Heart

Volumn 89, Issue 8, 2003, Pages 893-896

  Van Wissen, S ^a,b   Smilde, T J ^c   Trip, M D ^b   De Boo, Th ^c   Kastelein, J J P ^b   Stalenhoef, A F H ^c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0043169544     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.89.8.893     Document Type: Article

References (19)

1. Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol 1998;82:57-66U.
2. Hobbs HH, White AL. Lipoprotein(a): intrigues and insights. Curr Opin Lipidol 1999;10:225-36.
3. Superko HR. Did grandma give you heart disease? The new battle against coronary artery disease. Am J Cardiol 1998;82:34-46Q.
4. Berg K, Dahlen G, Christophersen B, et al. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian simvastatin survival study. Clin Genet 1997;52:254-61.
5. Price JF, Lee AJ, Rumley A, et al. Lipoprotein (a) and development of intermittent claudication and major cardiovascular events in men and women: the Edinburgh artery study. Atherosclerosis 2001;157:241-9.
6. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease - meta-analysis of prospective studies. Circulation 2000;102:1082-5.
7. Lingenhel A, Kraft HG, Kotze M, et al. Concentrations of the atherogenic Lp(a) are elevated in FH. Eur J Hum Genet 1998;6:50-60.
8. Smilde TJ, Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;357:577-81.
9. Smilde TJ, Trip MD, Wollersheim H, et al. Rationale, design and baseline characteristics of a clinical trial comparing the effects of robust vs conventional cholesterol lowering and intima media thickness in patients with familial hypercholesterolaemia. The atorvastatin versus simvastatin on atherosclerosis progression (ASAP) study. Clin Drug Invest 2001;20:67-79.
10. Maher VM, Brown BG. Lipoprotein (a) and coronary heart disease. Curr Opin Lipidol 1995;6:229-35.
11. Maher VM, Brown BG, Marcovina SM, et al. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995;274:1771-4.
12. Bredie SJ, Westerveld HT, Knipscheer HC, et al. Effects of gemfibrozil or simvastatin on apolipoprotein-B-containing lipoproteins, apolipoprotein-CIII and lipoprotein(a) in familial combined hyperlipidaemia. Neth J Med 1996;49:59-67.
13. Branchi A, Rovellini A, Fiorenza AM, et al. Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients. Int J Clin Pharmacol Ther 1995;33:345-50.
14. Haffner S, Orchard T, Stein E, et al. Effect of simvastatin on Lp(a) concentrations. Clin Cardiol 1995;18:261-7.
15. Goudevenos JA, Bairaktari ET, Chatzidimou KG, et al. The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia - a pilot study involving serial sampling. Curr Med Res Opin 2001;16:269-75.
16. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-13.
17. Hopkins PN, Stephenson S, Wu LL, et al. Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 2001;87:547-53.
18. Kroon AA, Aengevaeren WR, van der WT, et al. LDL-apheresis atherosclerosis regression study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996;93:1826-35.
19. Thompson GR, Maher VM, Matthews S, et al. Familial hypercholesterolaemia regression study: a randomised trial of low-density-lipoprotein apheresis. Lancet 1995;345:811-16.